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Abstract Clinical presentation of the chronic, herita-
ble condition cystic fibrosis (CF) is complex, with a
diverse range of symptoms often affecting multiple
organs with varying severity. The primary source of
morbidity and mortality is due to progressive destruc-
tion of the airways attributable to chronic inflammation
arising from microbial colonisation. Antimicrobial
therapy combined with practises to remove obstructive
mucopurulent deposits form the cornerstone of current
therapy. However, new treatment options are emerging
which offer, for the first time, the opportunity to effect
remission from the underlying cause of CF. Here, we
discuss these therapies, their mechanisms of action, and
their successes and failures in order to illustrate the shift
in the nature of how CF will likely be managed into the
future.
1 Common and Characteristic Pathologies
Associated with Cystic Fibrosis (CF)
Cystic fibrosis (CF) is a heritable, chronic condition
affecting multiple organs. The loss of or reduction in
function of the CF transmembrane regulator (CFTR), a
transmembrane ion channel through which chloride and
bicarbonate secretion are regulated, interferes with the
normal functioning of the epithelia within which it resides.
Functional CFTR is required to adequately hydrate the
airway surface liquid (ASL), the continuous transit of
which from the respiratory tract into the gastrointestinal
tract under ciliary movement aids in the preservation of
lung health and removal of inhaled microorganisms and
particles. People with CF, however, are unable to clear
their dehydrated airway mucous secretions, the prolonged
residence of which creates a niche that can be exploited by
a number of microorganisms. Many such colonising
microorganisms fail to be cleared by the immune system
and may persist for many years. Accordingly, this propa-
gates a continuous inflammatory state in the airway which
causes bronchiectasis, a progressive destruction of lung
tissue architecture. Morbidity of the pulmonary epithelium
is most directly responsible for the decreased lifespan
experienced by people with CF. Ultimately, mortality
results from asphyxiation due to progressive destruction of
lung tissue caused by chronic infection and a chronic
inflammatory response. Pulmonary insufficiency is the
hallmark of CF clinical presentation, and this is reflected
by the common use of the FEV1 (forced airway expiratory
volume in 1 s) test as an outcome for efficacy of inter-
ventions during clinical trials for CF.
In addition to the airway, pathologies are frequently
associated with each of the intestinal, biliary and pancreatic
mucosa. In the pancreas, CFTR is localised to the apical
surface of pancreatic duct cells [1], where it serves to
secrete bicarbonate [2], which facilitates raising of the
duodenal pH by pancreatic fluid secretions. CFTR defi-
ciency impairs the adequate exocrine functioning of the
pancreas [3], reducing fluid throughput, which serves to
concentrate secreted digestive enzymes. This, in turn, leads
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This leads to pancreatic fibrosis with consequent intestinal
malabsorption of nutrients, for which therapeutic supple-
mentation of digestive enzymes is required. Approximately
85 % of people with CF have pancreatic insufficiency [4],
with 87.3 % of patients in the USA requiring pancreatic
enzyme replacement therapy (PERT) in 2014 [5].
In addition to mediating compromised digestion,
defective CFTR mediates further pathology through the
pancreas: up to 50 % of people diagnosed with CF may
suffer from CF-related diabetes (CFRD). CFRD presents
atypically with respect to types 1 or 2 diabetes mellitus in
non-CF individuals [6], likely due to ancillary nutritional
deficiencies, and this can influence the diagnosis, with the
prevalence of the condition being approximately 6 % in
paediatric patients but rising to *50 % in adults [7].
Glucose-stimulated electrical conductance has long been
known to be involved in insulin secretion from pancreatic
b cells [8] and, given that CFTR is expressed on the sur-
face of b cells [9], the absence of CFTR has recently been
proposed to result in dysregulation of glucose-mediated
electrical activity, hence preventing insulin secretion from
pancreatic b cells in some people with CF [10].
Disease of the liver is also a notable contributor to the
overall pathology of CF. Epidemiological estimates of its
prevalence vary, with incidences of 2–41 % or more hav-
ing been reported from different studies [11–15]. CFTR in
the liver is localised to the luminal surface of intrahepatic
cholangiocytes of bile canaliculi [16], where it infuses
biliary secretions with bicarbonate in parallel to its function
in the pancreas, also serving to induce the efflux of bile
acids [17]. Thus, the absence of bicarbonate secretion
causes the retention of harmful bile acids within hepato-
cytes, inducing an inflammatory response, leading to
fibrosis analogous to that seen in the pancreas and, ulti-
mately, cirrhosis and portal hypertension [18].
The morbidities associated with pancreatic and hepatic
insufficiency can, in turn, cause a number of gastroin-
testinal sequelae [19], leading to a complex clinical pre-
sentation of people with moderate or severe disease
requiring multiple concurrent treatment and management
strategies. Indeed, several co-morbidities, such as pancre-
atic insufficiency and CFRD, correlate with lesser lung
function [20].
These morbidities and their ensuing therapies can have
adverse secondary effects when administered routinely for
chronic illness, with secondary kidney dysfunction being
an example of this. The kidney can be damaged by suc-
cessive rounds of non-steroidal anti-inflammatories,
aminoglycoside antibacterials, as well as chronic infection
itself, or CFRD and insulin treatment [21].
Each of these primary morbidities may individually or
interactively engender a number of potential acute or
chronic sequelae themselves requiring management for
patients [22].
2 Treatment Strategies
Myriad treatments are prescribed to address the compli-
cations engendered by the loss of CFTR function. The
majority of these abate the symptoms of this loss but
cannot restore the function of the proteins. As our under-
standing of the structure of native CFTR and its CF-caus-
ing mutants has improved, alongside the attendant
functional consequences of these, therapeutics that act to
express or restore CFTR have begun to emerge. A
remarkable diversity of these therapeutics is evident with
regard to their mechanisms of action (Fig. 1) and, as dis-
cussed here, a number of them are beginning to demon-
strate efficacy in trials or in the clinic.
2.1 Small-Molecule Therapies for Improving CF
Transmembrane Regulator (CFTR) Function
In excess of 2000 variants of the CFTR gene have been
described [23], with the consequence of each for the fate of
the protein falling into one of six classes (Fig. 2) [24, 25].
The first class results in CFTR simply being absent from
the cell by virtue of deletion of all or part of the gene, a
premature stop codon being introduced into the gene, a
frame-shifted gene or one which produces alternately
spliced messenger RNA (mRNA). The second class of
mutations comprise those that generate a protein incapable
of being trafficked to the membrane. Such misfolded pro-
teins are targeted for proteosomal degradation or remain in
a partially mature state in the cytoplasm or endoplasmic
reticulum. It is in this class that the common mutant,
p.Phe508del CFTR, lies.
Substitutions of amino acids in either nucleotide-binding
domain may yield a protein of sufficient structural nor-
malcy that it is trafficked to the membrane. However, such
mutations may result in a third class of defective proteins,
so-called gating mutants, whereby the chloride transport
capability of the protein is greatly reduced. Alternately, if it
possesses one of the fourth class of mutations, then an
incorrect amino acid in one of the membrane spanning
domains can alter the transmembrane pore sufficiently to
prevent conductance of chloride (or bicarbonate).
Normal physiological function requires not only native
CFTR but also sufficient levels of the protein. The fifth
class of mutations comprise those that result in the degra-
dation of some proportion of the mRNA, thus reducing the
quantity of CFTR produced. Similarly, the sixth class of
mutations give rise to CFTR that is recycled from the
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plasma membrane with a frequency that cannot sustain
normal levels of chloride throughput.
The first class of mutations that may afflict the CFTR
gene include those that result in the inclusion of a prema-
ture termination codon (PTC) in the sequence. This will, in
most cases, cause the degradation of the PTC-containing
mRNA or the truncated protein translated from it. Small-
molecule therapeutics have been developed that can induce
the read-through of the aberrant mRNA as normal [26].
Assuming that the PTC did not accompany a frameshift of
the ensuing mRNA sequence, a protein of potential nor-







Fig. 1 Prominent examples of
the broad array of therapeutic
strategies that are showing
promise for the instigation of
normal expression and function
of cystic fibrosis transmembrane
regulator (CFTR), and their
cellular targets. Ata ataluren,
GP67a-pDNA lipid-enclosed
DNA plasmid, Iva ivacaftor,






Fig. 2 Overview of the classes of defect into which mutant variants of cystic fibrosis transmembrane regulator (CFTR) may be categorised,
grouped according to which of the prominent chemotherapeutic agents are designed to compensate for said defect. mRNA messenger RNA
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extends to improving the likelihood of the correct peptidyl-
transfer RNA binding at the A site of the ribosome while
the PTC is present, overcoming the potentially deleterious
effect of the absence of an amino acid which the PTC
would otherwise cause.
One of the furthest-progressed PTC correctors in
development is PTC124 (generic name ataluren), being
brought to market by PTC Therapeutics (South Plainfield,
NJ, USA). It has advantageous potency and tolerability
relative to small molecules of comparable function and has
been shown to have encouraging efficacy in patients
amenable to treatment [27]. In assessing its physiological
effect in people with CF harbouring a class I mutation on at
least one allele, two open-label clinical trials demonstrated
an effect on nasal potential difference—a metric of CFTR
function—in the majority of patients over the durations of
study (Table 1) [28, 29]. No change in percentage FEV1
was apparent, though this was unsurprising given treatment
extended for only 6 weeks.
Ataluren has recently been subject to a randomised
controlled phase III trial in 238 patients who received the
drug for 48 weeks [30], with the primary outcome of the
study being lessening of the rate of decline of FEV1. Those
patients receiving treatment experienced a marginally les-
ser decline in FEV1 with respect to the control group
(2.5 % decline vs. 5.5 % decline; P = 0.12; Table 1). The
results of the study do not seem immediately impressive;
however, the ability of the drug to preserve patients’ lung
function over an extended period of time (years or decades)
would be a more informative and useful metric and a
halving of the rate of decline over 1 year, as this study
demonstrated, is encouraging.
Moreover, post hoc subgroup analysis demonstrated that
those patients who had received ataluren, but who were not
concurrently taking aminoglycoside antibacterials demon-
strated significantly less decline in FEV1 with respect to
their counterparts who had received placebo (0.7 vs. 6.4 %;
n = 44, P = 0.0082). This subgroup benefit likely stems
from the mechanism of aminoglycoside action in which
such compounds bind to ribosomal RNA [31]. Here, it may
interfere with the ability of ataluren to effect readthrough
of PTC-harbouring CFTR mRNA, positing discontinuation
of aminoglycoside treatment as an indication for positive
response to ataluren. This hypothesis is presently under
investigation in the form of a repeat study of the afore-
mentioned phase III trial specifically recruiting patients
who are not undergoing treatment with aminoglycoside
antibacterials [120].
For the majority of mutations, CFTR protein is pro-
duced, albeit in a non-functional form. This has provided
the opportunity for development of therapeutics that can
restore the normal functioning of the protein. Broadly
speaking, such therapeutics fall into one of two categories:
potentiators of CFTR open-conformation (enabling
throughput of greater quantities of chloride) and correctors
of CFTR structure (and, hence, function). Perhaps the most
prominent example of a therapeutic targeting the defective
CFTR itself is the small molecule, ivacaftor (brand name
Kalydeco), developed by Vertex Pharmaceuticals (Bos-
ton, MA, USA).
Ivacaftor was designed to potentiate the channel opening
of CFTR bearing a class III single-nucleotide polymor-
phism, Gly551Asp, and received US FDA approval for the
treatment of people with CF bearing this mutation—rep-
resenting *5 % of patients—in 2012 [32]. It had demon-
strated statistically significant therapeutic efficacy, with
respect to control subjects who continued standard treat-
ment, in two randomised controlled phase III trials and a
subsequent open-label extension over 48 weeks and up to
144 weeks, respectively (Table 2) [33–35]. Each trial uti-
lised the common primary endpoint of improvement or
lesser decline in FEV1. The drug not only halted decline in
FEV1 but improved it relative to the baseline established at
the trials’ outset, displaying an *10 % improvement in
FEV1 [36].
Given its efficacy when administered to patients
homozygous for the Gly551Asp mutation, ivacaftor was
then trialled in patients homozygous for Phe508del; how-
ever, it failed to demonstrate a significant change in FEV1
relative to control subjects [37], reflecting the difference in
the nature of the defect affecting CFTR. Nonetheless,
ivacaftor treatment appears to be a potent and efficacious
therapy for adults with CF who harbour homozygous
Gly551Asp mutant CFTR alleles; it improves FEV1 and
weight gain as well as reducing incidence of infection by
Pseudomonas aeruginosa and prolonging intervals
between pulmonary exacerbations [38]. The drugs’ efficacy
in patients who have other class III mutations has also been
demonstrated clinically [39], leading to its approval as a
treatment in patients harbouring such mutations, as well as
in patients with p.Arg117His CFTR [32]. It may also prove
useful for patients who have other ‘partial function’
mutations (classes III–V), further extending its reach.
Moreover, lesser doses are being trialled in paediatric
patients to assess tolerability, as CF pathology is often
apparent in infancy [40, 41]; ivacaftor treatment is pre-
sently approved to commence from 2 years of age [32].
While the requirement for early intervention is apparent,
this is accompanied by several caveats. As mentioned,
tolerability is an issue, given the load placed particularly on
the hepatic cytochrome, cytochrome P450 3A (CYP3A), by
ivacaftor [40]. In addition, the yearly cost per patient of
ivacaftor treatment is considerable—£182,000 per patient
per year in the UK—leading to stringent assessment of its
clinical benefit [42, 43], which may limit the breadth of
patients to whom it will be administered.
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Concern over the costings of new investigational drugs
for ostensibly orphan conditions may be tempered some-
what by the nature of the re-distribution of revenue. The
arrangement in place between Vertex Pharmaceuticals and
the Cystic Fibrosis Foundation—the US-based not-for-
profit CF research organisation, whose model of venture
philanthropy has seen it receive *US$3.3 billion in drug
royalties in 2014 [44]—may help to ensure continued high
levels of research into the condition.
Vertex Pharmaceuticals has also progressed to clinical
trials with a therapeutic, generic name lumacaftor,
designed to assist in the trafficking of Phe508del CFTR to
the epithelial membrane [45]. Despite in vitro mechanistic
evidence, phase II trials failed to show a benefit of taking
lumacaftor for patients homozygous for the Phe508del
mutation (Table 3) [46], which represents the genotype of
approximately 50 % of CF patients in both the EU and
USA [22]. Accordingly, it was decided to combine luma-
caftor treatment with ivacaftor treatment on the basis that
ivacaftor may prove effective once Phe508del CFTR had
been trafficked. Phase II trials of several dosage permuta-
tions of this combined therapy showed a modest
improvement in FEV1 at high doses of each therapy:
600 mg of lumacaftor once daily and 250 mg of ivacaftor
once daily [47]. Patients in this treatment arm demon-
strated a 5.6 % improvement in % FEV1, and, as such, this
regimen was progressed to two phase III trials which are
currently undergoing open-label extensions having com-
pared 600 mg lumacaftor once daily vs placebo and
400 mg lumacaftor twice daily vs placebo, respectively
[48]. The aforementioned phase III trials each demon-
strated significant improvement in percentage FEV1 and
other metrics (Table 3). Accordingly, licensing for a
combination therapy of lumacaftor and ivacaftor (trade
name OrkambiTM) has been approved by the FDA [49].
There are other novel therapeutics following in the
developmental pipeline of Vertex Pharmaceuticals, focused
on the major mutations in CF. The furthest progressed of
these is another corrector of Phe508del CFTR, designated
VX-661. This has shown an ability to improve CFTR
operation in vitro and seems to be well-tolerated in patients
with some efficacy when administered in conjunction with
ivacaftor [50].
The same defects are currently being targeted by other
companies or institutions. For example, Novartis have
developed a series of correctors for Phe508del CFTR that
possess similar functional activity to those of the Vertex
therapeutics [51]. Many other candidate chemical entities
have so far been declared to have efficacy in restoring
CFTR function in vitro and, undoubtedly, further useful
therapies will emerge during clinical trials [36].
The current high cost of the ivacaftor regimen had raised











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 M. P. Murphy, E. Caraher
schemes or insurance providers. However, given the larger
cohort of patients eligible to receive OrkambiTM, the latter
regimen has been offered at a cost lower than that for the
ivacaftor monotherapy [52], which may facilitate its pre-
scription to patients. Longer term, however, a proliferation
of personalised medicines for CF seems unsustainable from
an economic standpoint and there are numerous calls for
action to be taken to ensure that costs are controlled, while
preserving research investment [43, 53].
2.2 Gene Therapy for the Restoration of Normal
CFTR Function
While antibacterial use is frequent in clinical treatment of
CF, arguably the most direct route to treating CF, as well as
CFTR-related diseases, would be to integrate the native
gene into airway stem cells in vivo. Such integrating vec-
tors exist [54] but have been demonstrated to be oncogenic
in some settings, justifiably giving rise to concerns over the
use of integrating gene therapy [55]. The next best option
would be to introduce copies of the native CFTR gene into
the cells of the affected epithelia. Encouraging work has
been carried out in vitro in this regard. Introduction of the
native CFTR gene into CFTR-deficient airway epithelial
cell line cells—via a transformed human parainfluenza
virus—has been shown to result in the expression of the
protein in those cells [56]. Furthermore, that study high-
lighted that normal ASL height was restored above the cell
layer following induction of expression in as few as 25 %
of the cells, lessening the issues of bioavailability and
transfection efficiency of the vector.
The utility of virally mediated gene delivery has
potential issues of toxicity or interference with cell func-
tioning derived from the virus’ actions. These problems
were encountered during efforts to use respiratory aden-
oviruses as delivery vectors; while they possessed a natural
ability to traverse the airway epithelium, immune responses
curtailed the expression of adenoviral transgenes [57].
As such, design of a viral delivery vector should account
for these factors and further modifications to the virus, such
as rendering it more immunotolerable, may be necessary to
lessen its negative impact [58]. Even overcoming these
issues, the turnover of epithelial cells requires the repeated
administration of the vector throughout the life of the
patient, ultimately resulting in failure of the virus due to its
recognition and destruction by the immune system. This
would, in turn, place a burden on the development of these
viral vectors as they would require continual re-engineer-
ing and, hence, renewed regulatory approval.
Tolerance by the immune system for a given virus
would render it amenable to repeated administration, but a
virus possessing this property alongside an ability to infect
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not been described. This has, however, been overcome by
the generation of chimeric viruses possessing each of these
traits: the well-tolerated lentivirus, simian immunodefi-
ciency virus, was transformed with coat proteins of the
respiratory infectious agent, Sendai virus, producing a virus
that possessed the favourable traits of both [59].
Given the complexities inherent in developing viruses as
vectors for gene therapy, alternate vectors for the delivery
of CFTR DNA are under investigation. For example, pH-
responsive peptides may be used. These peptides are bound
to nucleic acids and remain so during endocytosis, subse-
quently enabling the escape of the nucleic acid from the
endosome through a pH-dependent conformational change
which disrupts the endosomal membrane [60]. Such a
delivery vector avoids much of the immunogenicity
inherent in a virus.
It should be noted that, while CF is a disease affecting
multiple organs, correction of defects in the airway will
provide a significant improvement in the quality of
patients’ lives as well as an extension of their lifespan and
has been pursued most extensively for this reason, in
conjunction with the supposed ease of delivery of therapies
via inhalation. However, the mucous layer presents an
obstacle to delivery of therapeutics in this setting. For
(relatively) small-molecule therapeutics, access to the
epithelium may be improved by coating them in a non-
mucous-adhesive compound such as polyethylene glycol
(PEG), the efficacy of which can be further improved by
coadministration with a mucolytic agent such as N-acetyl
cysteine [61].
Combining a non-viral vector with each of these traits
would represent a promising gene therapy for the treatment
of CF lung disease. To that end, the UK CF Gene Therapy
Consortium have collectively progressed research into such
a vector. A plasmid harbouring CFTR was depleted of pro-
inflammatory CpG motifs and encapsulated within a pro-
prietary cationic lipid, GL67 (developed by Genzyme,
Cambridge, MA, USA), in conjunction with the neutral
lipid dioleoylphosphatidylethanolamine and a PEG-con-
taining fusion lipid (Fig. 1). This has been shown in a
murine study to have a favourable tolerability and induce
persistent expression of CFTR, and each of these charac-
teristics were maintained throughout the repeated-dose
study [62].
The outcome of this study gave rise to a phase IIb
clinical trial of the formulation. It was demonstrated that
administration of a once-monthly dose of the formulation
detailed above over 12 months arrested the decline in
FEV1 percentage for treated patients with respect to those
who had received nebulised saline as placebo (-0.4 vs. -
4.0 %, respectively; Table 4) [63]. While modest in size, it
is notable that some treated patients had better responses
than others, which indicates that a study powered to
identify subgroup effects may lead to further improvement
in the utility of the therapy. Moreover, adverse events were
comparable to the placebo-treated cohort and response did
not depend on the type of CFTR mutation borne by patients
(with respect to Phe508del status).
Successful transfection of airway cells with the CFTR
gene subsequently requires it to be expressed. The plasmid
being utilised by the UK CF Gene Therapy Consortium
harbours a humanised promoter to ensure expression, but a
number of other groups have sought to correct the sequence
that already exists. The recent advent of genome editing
tools has made this feasible. One such tool, which has been
applied to the introduction of CFTR into the genome, is
zinc finger nuclease (ZFN) technology. This comprises a
fusion protein, one domain of which specifically recognises
Table 4 Selected data from prominent clinical trials of other interventions, curative or palliative, against cystic fibrosis lung disease















62 (50) 23.6 (10.8) pGM169/GL67A
5 mL/28 daysa




54 (46) 26 (13) Placebo: 0.9 %
saline/28 days





334 (44.6) 21.3 (10.7) Inhaled mannitol
400 mg twice daily
63.6 (25–105) 26 3.6c [78]
232 (49.8) 21.6 (10.5) Inhaled mannitol
50 mg twice daily
61.9 (30–100) NA
CI confidence interval, FEV1 forced airway expiratory volume in 1 s, NA not applicable, RCT randomised controlled trial, SD standard deviation
a ±5 days
b Relative change with respect to baseline
c Difference between groups in absolute % FEV1
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short (9–12 bp) sequences of DNA, while the other pos-
sesses non-specific endonuclease activity capable of
introducing double-strand breaks into the DNA at the tar-
geted site, allowing the sequence of interest to insert [64].
Such ZFN complexes form heterodimers to carry out this
activity, enabling the recognition of *18 bp sequences,
hence providing a high degree of specificity [65]. This
approach has been demonstrated in vitro to correct the
defective CFTR sequence in epithelial cells having the
c.1521_1523delCTT genotype, which gives rise to the
Phe508del mutant CFTR [66].
3 Indirect Therapies for CF Management
3.1 Putative Mediators of Improved Lung
Physiology
Concurrent efforts are also ongoing to correct the defective
physiology evident in CF by compensating for the lack of
functional CFTR, a strategy that has the advantage of being
applicable to all patients with CF. Most directly, increasing
the activity of alternative chloride channels could, in
principle, restore the native phenotype of the mucosal
epithelium. For example, the calcium-activated chloride
channel, TMEM16A, is expressed on airway goblet cells
(which secrete mucins) and contributes to mucin release
[67]. Mouse ASL height is also regulated by TMEM16A
[68]. A direct-acting, long duration pharmacological
modulator of TMEM16A is currently being sought [69].
Alternatively, modulation of sodium absorption, which is
hyperactive in CF, may be considered [22]. The epithelial
sodium channel (ENaC) has been explored in this context,
with some therapeutics having reached clinical trials before
ultimately being rejected on the basis of lack of efficacy due
to insufficient potency or duration of effect or adverse effects
such as pulmonary oedema [70, 71]. Efforts in this regard are
continuing to pursue longer-acting modulators of ENaC,
with some demonstrating increased ASL height and
mucociliary clearance in animal models [72].More recently,
however, additional regulators of ENaC have been descri-
bed, offering targets for candidate drugs with more finely
tuned effects [73]. Similarly, the chaperones that guide the
folding and trafficking ofCFTR itself have been proposed for
therapeutic action, which would be of particular benefit to
class II mutations that do not reach the plasma membrane
and class V mutations where CFTR is recycled from the
membrane too quickly [74].
Given the attractiveness of ostensibly curing a chronic,
debilitating, life-shortening condition, combined with the
apparent requirement to take the aforementioned thera-
peutics for the duration of life [75], there is considerable
research endeavour taking place into their further
improvement. Presumably, the combined efforts of various
entities in this regard will eventually yield an effective,
persistent correctional treatment, but in the intervening
years palliative therapy remains the best available option.
One such therapy concerns emulating the effect of ASL
hydration, which is lacking in CF, by inducing osmosis of
water from the airway cells into the luminal space through
the inhalation of nebulised hyperosmolar solutions or dry
powders. Two such osmolytes are in use: hypertonic saline,
which overcomes ENaC-mediated hyper-absorption of
sodium, and mannitol, which also establishes an osmotic
driving force; both of which also induce coughing, thereby
helping to dislodge deposited mucous. In concentrations as
high as 6 %, hypertonic saline has been demonstrated to
improve lung function after 16 weeks of therapy [76];
extension of therapy to 48 weeks failed to confirm
improved lung function but did extend the duration
between pulmonary exacerbations [77], highlighting the
utility of clearing the lungs of deposited material. By
comparison, two recent phase III trials of inhaled mannitol
demonstrated improved lung function for up to 26 weeks
(the duration of the studies) and prolonged the interval
between exacerbations (Table 4) [78].
There is potential for incidental effects of mannitol
administration, with in vitro evidence suggesting that the
presence of mannitol can induce sensitivity to the
antibacterial tobramycin in P. aeruginosa biofilm persister
cells [79], presumably due to carbon source recognition by
the bacteria leading to their ‘awakening’. Similarly, man-
nitol may enhance adhesion by CF-associated Burkholderia
multivorans strains [80], illustrating a potential need for
concurrent antibacterial treatment with mannitol therapy.
Treatment with recombinant human deoxyribonuclease
(rhDNase), also known as dornase alfa or pulmozyme,
represents another measure commonly employed to aid
breathing by clearance of pulmonary obstructions.
rhDNase treatment degrades the DNA derived from lysed
neutrophil infiltrates, enabling easier clearance by airway
clearance techniques such as saline therapy or thoracic
agitation to induce coughing [81]. This treatment can
improve lung function, though its efficacy in reducing
exacerbations is less clear [82]. It may also be useful for
disruption of microbial biofilms in the airways [83].
Given that lung damage driven by inflammation is the
major contributor to mortality in people with CF, inhaled
corticosteroids are often prescribed to lessen the extent of
inflammation experienced by patients. Oral prednisone had
been tested under clinical trials, lasting up to 48 months,
and has shown improvements in patients’ lung function
[84, 85]. However, an increase in adverse events compared
with the placebo group was evident and age-matched
growth impairment was noted among males for up to
several years following discontinuation of treatment [86].
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A recent systematic review of trials of inhaled corti-
costeroids (n = 13) failed to find a significant improve-
ment in patients’ health while participating in those studies
[87]. The authors noted that withdrawal from corticos-
teroids often took place without issue and highlighted
possible negative side effects from taking them, in a par-
allel to the experience with oral prednisone. As a coun-
terargument to the lack of trial evidence, such trials were
conducted for only a limited period of time in patients who
have already experienced prolonged inflammation. They
cannot reflect any benefit that early, prolonged intervention
with corticosteroids may have.
Improvement of patient health can not only enable better
outcomes to treatment and immunity to exacerbations but
can improve the quality of patients’ lives. To that end,
pancreatic or hepatobiliary insufficiency are often com-
pensated for by supplementation with digestive enzymes
and vitamins specific to the needs of the patient, alongside
maintenance of a high-calorie diet that emphasises high
intake of fat and protein [88].
PERT is widely used; porcine-derived pancrelipase has
demonstrated tolerability and mediates improvements to
absorption of fats and nitrogenous compounds, hence
contributing to restoration of normal growth and mainte-
nance of adequate weight [89]. Porcine-derived native
enzymes do, however, present challenges regarding dosage
and efficacy during gastrointestinal transit [90]. Accord-
ingly, non-animal-derived PERT agents are being pursued
with liprotamase, for example, having demonstrated clini-
cal efficacy and presently undergoing further investigation
[91, 92]. Similarly, microbially derived lipases may be
effective as PERT agents and are under clinical investi-
gation [93]. Bile acids are also administered for those
patients experiencing CF liver disease, though their effi-
cacy is questionable [94] and probably dependent on the
residual functioning of the liver among other factors such
as age at intervention [95].
3.2 Antimicrobial Agents
Strategically related to amelioration of inflammation is the
removal of its cause, namely the colonisation of patients’
lungs by microorganisms. Numerous species of microor-
ganisms are frequently isolated from CF lung sputum
samples, most commonly P. aeruginosa, Staphylococcus
aureus, Haemophilus influenzae, as well as the fungal
pathogen Aspergillus fumigatus and members of the
Burkholderia cepacia complex of bacteria (Bcc), but a host
of others are also frequently detected by routine culture
including Stenotrophomonas maltophilia, non-tuberculous
mycobacteria, etc. [96, 97].
P. aeruginosa, for example, has a prevalence ranging
from 13 to 75 % of CF patients, depending on age and
geographic location [96, 98]. Its prevalence increases
steadily with age (from*25 % at the onset of adolescence
to *75 % at adulthood in the US population), reflecting
the tendency for many patients to become chronically
colonised with a given strain with worsening airway con-
ditions, often defined as greater than 50 % of their sputum
samples being culture positive over a 12-month period
[99]. A recent study in the USA indicated that as many as
48 % of people with CF become colonised with
P. aeruginosa by the age of 6 years (n = 3608) [100].
Concurrently, the rate of pulmonary exacerbations signifi-
cantly increases in patients following acquisition [101].
The overall prevalence of P. aeruginosa is falling, as
evident in US patient registry data, which can be attributed
to the success of early and frequent intervention with
antibacterials such as inhaled tobramycin or aztreonam
[102, 103]. A number of trials have demonstrated the utility
of inhaled antibacterials for improving lung function and
lessening the rate of pulmonary exacerbations in patients
with long-term colonisation by P. aeruginosa [104].
Moreover, if treatment with antibacterials of proven effi-
cacy is commenced soon after acquisition of the bacterium,
it is possible to effectively eradicate P. aeruginosa [103].
While many patients for whom P. aeruginosa is suc-
cessfully eradicated following early intervention were
shown to sustain the absence of the bacterium for at least
5 years, many failed to demonstrate an improvement in
their rate of pulmonary exacerbation [105]. This may
suggest that other microorganisms then dominate, empha-
sising that effective antimicrobial regimens against a broad
range of CF-associated pathogens is needed. This presents
a challenge where microorganisms of low prevalence are
concerned, as trials of the efficacy of candidate therapies
may be under-powered.
Considering the example of colonisation by species of
Burkholderia bacteria, their multi-drug-resistant status has
precluded the instigation of a standard course of treatment.
This is brought into sharp relief by the failure of a recent
review, carried out by the Cochrane collaboration, to find
even a single eligible trial of effective interventions against
Bcc bacteria [106]. Clinical trials are also lacking inter-
ventions against the increasingly prevalent methicillin-re-
sistant S. aureus (MRSA) [107], S. maltophilia [108] or
non-tuberculous mycobacteria [109].
Such endeavours are not trivial, however, as evidenced
by findings from systematic reviews of trials of antibacte-
rial interventions against chronic P. aeruginosa colonisa-
tion. A recent review of trials of oral antibacterials for the
treatment of P. aeruginosa failed to find a notable im-
provement to either lung function or quality of life [110].
The authors highlighted both the subjectivity of quality-of-
life assessments, as well as the differential response of
different patients to a given treatment (into which
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contribute myriad factors). This situation is echoed in a
review of studies of inhaled tobramycin for treatment of
chronic P. aeruginosa colonisation [102], in which the
ability to improve clinical condition in the majority of
patients was clear, but the failure of some patients to
respond confounded large-scale analyses of antibacterial
efficacy.
In a more general sense, the preferential route of
antibacterial administration has proven equally difficult to
confirm, with none of oral, intravenous or nebulised
administration emerging as clearly more efficacious in
treating pulmonary exacerbations [111]. However, for
long-term therapy, inhalation may have an advantage,
particularly in the case of inhaled tobramycin [112, 113]. It
is also recognised that the propensity of successful
colonisers to form biofilms may necessitate the adminis-
tration of types and concentrations of antibacterials with
anti-biofilm efficacy, though solid confirmation of this has
not yet been provided [114].
Hence, treatment decisions are informed by prior
experience and case reports. In the case of Burkholderia
bacteria, there are isolated case studies of successful
eradication of Burkholderia from CF patients and from
settings other than CF, such as successful intervention with
aztreonam in non-CF bronchiectasis [115]. However, while
early eradication is often attempted, using combined
intravenous and nebulised antibacterials, the success rate is
low, with many infections remaining in situ [116].
3.3 Transplant
Management of the CF pulmonary physiology and micro-
biome is a matter of delaying the decline in lung function,
but inevitably patients are rendered unable to achieve
sufficient oxygen intake through breathing and, as they
approach this point, bilateral lung transplantation is con-
sidered. In a retrospective study of 101 transplantations in
CF patients in Italy, the 1-, 5- and 10-year survival rates for
patients post-transplantation were 79, 58 and 42 %,
respectively, while FEV1 increased from a pre-operative
mean of 22 to 85 % 1 year after the operation [117].
Interestingly, these figures match those of a UK cohort of
transplant recipients, with mean FEV1 for those patients
improving from 21 to 78 % at 1 year, while survival rates
were 82 % at 1 year, 62 % at 5 years and 51 % at 10 years
(n = 176) [118].
Hence, there is a substantial survival and life-quality
advantage to be gained through transplantation. Although
there was sizable post-operative mortality (14.8 % of
patients in the Italian clinic), the potential benefits may be
decisive in listing patients for transplant. Supplementary to
this, many clinics view colonisation by certain bacteria,
such as Burkholderia, as a contra-indication for
transplantation. In a UK CF clinic, *10 % of CF patients
who underwent lung transplantation had colonising
Burkholderia. Of these, *40 % died within a year fol-
lowing the operation, with the most frequent cause of death
being sepsis [119]. This greatly exceeded the mortality rate
for patients who did not harbour these bacteria, and these
outcomes led to that clinic ceasing to list CF patients who
harbour Burkholderia for transplantation.
4 Concluding Remarks
CF causes chronic morbidity in multiple organs, leading to
a substantial reduction in the lifespan of those affected.
Loss of lung function, mediated by tissue destruction pur-
suant to microbial colonisation and the attendant inflam-
matory response, is the most pronounced driver of
mortality for people with CF. As such, multiple avenues of
therapeutic interventions are being pursued. Ultimately,
restoration of the airways to a normal phenotype holds the
most promise for meaningful extensions of survival for
people with CF, whether by allowing the epithelium to
produce normal CFTR or by restoring the normal function
of existing CFTR. In the meantime, diminishing the
microbial burden in the airways is an important focus of
research, but requires potent antibacterials and better
delivery of them. These interventions are greatly aided by a
therapeutic strategy that addresses as many of the symp-
toms of CF as possible; the resulting improvements to
organ function and, hence, quality of life are instrumental
in continuing to extend the lives of people with CF.
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